Paper Details

  1. Home
  2. Paper Details

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.

Author: AricòEleonora, BelardelliFilippo, BelliRoberto, BuccioneCarla, CaponeImerio, CappelliniGiancarlo Antonini, CarleiDavide, CasorelliIda, CastielloLuciano, D'AgostinoGiuseppina, MacchiaIole, MarchettiPaolo, MonqueDomenica, MontefioreEnrica, MoschellaFederica, NapolitanoMariarosaria, PavanAntonio, ProiettiEnrico, RizzaPaola, RozeraCarmela, SantodonatoLaura, SestiliPaola, UrbaniFrancesca

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study explores the potential of using dendritic cells (DCs) generated in the presence of interferon-alpha (IFN-DCs) for immunotherapy of advanced melanoma patients. IFN-DCs are capable of efficiently uptaking, processing, and cross-presenting antigens to T cells, and combining this with tumor-destructing therapies may trigger an antitumor immune response.
Paper Details　
Original Abstract of the Article :
Advanced melanoma patients have an extremely poor long term prognosis and are in strong need of new therapies. The recently developed targeted therapies have resulted in a marked antitumor effect, but most responses are partial and some degree of toxicity remain the major concerns. Dendritic cells p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438625/

データ提供：米国国立医学図書館（NLM）

A New Approach to Treating Advanced Melanoma: Combining Dendritic Cells and Dacarbazine

Advanced melanoma is a challenging type of skin cancer with a poor prognosis. This study explores a new approach to treating advanced melanoma using a combination of dendritic cells and dacarbazine. Dendritic cells are a type of immune cell that plays a key role in activating the immune system. The researchers developed a strategy to stimulate the immune system by injecting dendritic cells into the tumor, followed by treatment with dacarbazine, a chemotherapy drug. The study found that this combination therapy was able to activate antitumor immunity, leading to a reduction in tumor size in some patients.

A New Oasis in the Desert of Melanoma: Combating Cancer with the Immune System

This study offers hope for patients with advanced melanoma by exploring a new approach that uses the body's own immune system to fight cancer. The combination of dendritic cell injections and dacarbazine treatment appears to stimulate antitumor immunity, potentially leading to improved outcomes for patients.

The Future of Cancer Treatment: Harnessing the Power of the Immune System

This research is a testament to the evolving field of cancer treatment, where researchers are exploring new and innovative approaches to harness the power of the immune system to fight cancer. The use of dendritic cells in cancer immunotherapy is a promising area of research that could lead to breakthroughs in the treatment of various cancers.

Dr.Camel's Conclusion

This research embarks on a journey through the desert of advanced melanoma, seeking new treatment approaches. The study explores the potential of combining dendritic cells and dacarbazine, a strategy that could empower the immune system to fight cancer. This research offers a glimmer of hope in the battle against melanoma, a testament to the ongoing search for new and effective therapies.

Date :
  1. Date Completed 2016-04-19
  2. Date Revised 2021-01-02
Further Info :

Pubmed ID

25933939

DOI: Digital Object Identifier

PMC4438625

Related Literature

Article Analysis
・Side Effects of dacarbazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.